Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Vor Biopharma (VOR) and Bristol-Myers Squibb (BMY)

Tipranks - Tipranks - Thu Apr 9, 6:26AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insmed (INSM), Vor Biopharma (VOR) and Bristol-Myers Squibb (BMY) with bullish sentiments.

Easter Sale - 70% Off TipRanks

Insmed (INSM)

In a report released yesterday, Vamil Divan from Guggenheim maintained a Buy rating on Insmed, with a price target of $227.00. The company’s shares closed last Tuesday at $163.03.

According to TipRanks.com, Divan is a 5-star analyst with an average return of 9.8% and a 56.3% success rate. Divan covers the Healthcare sector, focusing on stocks such as Unicycive Therapeutics, Eledon Pharmaceuticals, and Travere Therapeutics. ;'>

Currently, the analyst consensus on Insmed is a Strong Buy with an average price target of $215.53, representing a 32.4% upside. In a report issued on March 24, TipRanks – Google also upgraded the stock to Buy with a $159.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Vor Biopharma (VOR)

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Vor Biopharma today and set a price target of $40.00. The company’s shares closed last Tuesday at $16.85.

According to TipRanks.com, Willey is a 4-star analyst with an average return of 7.3% and a 42.0% success rate. Willey covers the Healthcare sector, focusing on stocks such as Compass Therapeutics, AbCellera Biologics, and Abeona Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vor Biopharma with a $37.00 average price target, a 135.2% upside from current levels. In a report issued on March 29, Jefferies also initiated coverage with a Buy rating on the stock with a $50.00 price target.

Bristol-Myers Squibb (BMY)

Guggenheim analyst Seamus Fernandez reiterated a Buy rating on Bristol-Myers Squibb yesterday and set a price target of $72.00. The company’s shares closed last Tuesday at $57.67.

According to TipRanks.com, Fernandez is a 5-star analyst with an average return of 25.8% and a 60.7% success rate. Fernandez covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Sagimet Biosciences, Inc. Class A, and Mineralys Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bristol-Myers Squibb with a $62.94 average price target, a 6.5% upside from current levels. In a report issued on April 6, Piper Sandler also reiterated a Buy rating on the stock with a $75.00 price target.

Read More on INSM:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).